COVID19 and human reproduction joint statement
Declaration of principle
- Advocate for the well-being of patients.
- Monitor local conditions, including prevalence of disease, status of government or state regulations, and availability of resources.
- Implement proactive risk assessment within their practices prior to restarting services.
- Prioritize care and judiciously allocate use of limited resources using medical criteria.
- Counsel patients about all options, including deferring evaluation and treatment.
- Adhere to active risk mitigation strategies to reduce the risk of viral transmission.
- Develop clear and codified plans to ensure the ability to provide care while maximizing the safety of their patients and staff.
- Remain informed and stay current regarding new medical findings.
- Develop or refine robust emergency plans.
- Be prepared to interrupt medical treatment if conditions warrant discontinuation.
- Reproductive medicine professionals and practices are essential front-line resources for screening, monitoring, and assessing the prevalence and impact of the disease on patients and their progeny through Point-of-Care data collection.
- ESHRE, ASRM and IFFS are committed to continuous monitoring of the effects of COVID-19 on gametes and reproductive tissues, collecting data on pregnant patients infected during the pandemic, and assessing the outcomes of mothers and neonates.
- Examples of these research and registry efforts follow:
- In the U.S.A., the ASPIRE (Assessing the Safety of Pregnancy In the Coronavirus Pandemic) Study is a nationwide prospective cohort study of pregnant women and their offspring during the COVID-19 pandemic. All patients under the care of a reproductive medicine specialist who conceived spontaneously or with assisted reproductive technology (ART) between March 1st and December 31st are encouraged to participate.
- ESHRE is gathering global case-by-case reporting on the outcome of medically assisted reproduction (MAR) conceived pregnancies in women with a confirmed infection (https://nl.surveymonkey.com/r/COVID19ART).
- The affiliate society of ASRM, the Society for Assisted Reproductive Technologies (SART) is including mandatory COVID-19-related questions in their Clinic Outcome Reporting System (CORS) registry of assisted reproductive technologies (ART), which accounts for over 95% of all ART cycles in the U.S.A.
- ESHRE is gathering data and mapping MAR/ART activity during the pandemic, country by country whether and /or when they stopped offering treatment and when they have resumed care.
- IFFS is conducting COVID-19-related periodic surveys to assess global trends in access to MAR/ART services.
Anna Veiga – ESHRE/Spain
Luca Gianaroli – ESHRE/Italy
Steve Ory – IFFS/USA
Marcos Horton – IFFS/Argentina
Eve Feinberg – ASRM/USA
Alan Penzias – ASRM/USA